Abstract
Ropivacaine, the S-(-)-enantiomer of N-(2,6-dimethylphenyl)-1-propyl-2-piperidinecarboxamide is a new long-acting local anesthetic. This review demonstrates that it is effective in brachial plexus anesthesia. It is at least as efficient as bupivacaine in terms of quality, duration of analgesia, anesthesia, and motor block. It could have some advantages over bupivacaine in terms of onset time of sensory and motor block, but this remains controversial. In single-shot brachial plexus block, it is equipotent to bupivacaine and has a similar pharmacokinetic profile. Its minimal effective concentration is 0.5percent, and the benefit of increasing its concentration to 0.75 or 1percent remains debatable. Its use during continuous brachial plexus block has been much less studied, and conflicting results involving efficacy during continuous interscalene block and inefficacy during continuous axillary block have been obtained. Further investigations are required to assess its efficacy during such block.XXXYYYZZ Z Because of lower CNS and cardiac toxicity, ropivacaine is safer than bupivacaine. It would be thus the preferred local anesthetic for brachial plexus blockade when long-lasting anesthesia and analgesia is required.
Keywords: Ropivacaine, PERIVASCULAR BRACHIAL, Single-shot Interscalene, bupivacaine
Current Topics in Medicinal Chemistry
Title: Clinical Application of Ropivacaine for the Upper Extremity
Volume: 1 Issue: 3
Author(s): F. J. Singelyn
Affiliation:
Keywords: Ropivacaine, PERIVASCULAR BRACHIAL, Single-shot Interscalene, bupivacaine
Abstract: Ropivacaine, the S-(-)-enantiomer of N-(2,6-dimethylphenyl)-1-propyl-2-piperidinecarboxamide is a new long-acting local anesthetic. This review demonstrates that it is effective in brachial plexus anesthesia. It is at least as efficient as bupivacaine in terms of quality, duration of analgesia, anesthesia, and motor block. It could have some advantages over bupivacaine in terms of onset time of sensory and motor block, but this remains controversial. In single-shot brachial plexus block, it is equipotent to bupivacaine and has a similar pharmacokinetic profile. Its minimal effective concentration is 0.5percent, and the benefit of increasing its concentration to 0.75 or 1percent remains debatable. Its use during continuous brachial plexus block has been much less studied, and conflicting results involving efficacy during continuous interscalene block and inefficacy during continuous axillary block have been obtained. Further investigations are required to assess its efficacy during such block.XXXYYYZZ Z Because of lower CNS and cardiac toxicity, ropivacaine is safer than bupivacaine. It would be thus the preferred local anesthetic for brachial plexus blockade when long-lasting anesthesia and analgesia is required.
Export Options
About this article
Cite this article as:
Singelyn J. F., Clinical Application of Ropivacaine for the Upper Extremity, Current Topics in Medicinal Chemistry 2001; 1 (3) . https://dx.doi.org/10.2174/1568026013395326
DOI https://dx.doi.org/10.2174/1568026013395326 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Erectile Dysfunction and Diabetes Mellitus: Mechanistic Considerations from Studies in Experimental Models
Current Diabetes Reviews Potential Application of Antimicrobial Peptides in the Treatment of Bacterial Biofilm Infections
Current Pharmaceutical Design Αlpha-2 Adrenergic and Opioids Receptors Participation in Mice Gastroprotection of Abelmoschus esculentus Lectin
Current Pharmaceutical Design Hepatocellular Carcinoma: Important Biomarkers and their Significance in Molecular Diagnostics and Therapy
Current Medicinal Chemistry Complications of Anti-Vascular Endothelial Growth Factor Drugs
Current Drug Therapy Low Molecular Weight Heparin: Current Evidence for Its Application in Orthopaedic Surgery
Current Vascular Pharmacology Therapeutic Effects of Renal Denervation on Renal Failure
Current Neurovascular Research Platelet Resistance to the Anti-Aggregating Agents in the Insulin Resistant States
Current Diabetes Reviews Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry The Applications of Biomarkers in Early Clinical Drug Development to Improve Decision-Making Processes
Current Clinical Pharmacology Nanocarriers for Tracking and Treating Diseases
Current Medicinal Chemistry Midazolam Plus Haloperidol as Adjuvant Analgesics to Morphine in Opium Dependent Patients: A Randomized Clinical Trial
Current Drug Abuse Reviews Review: New Anti-Cytokines for IBD: What is in the Pipeline?
Current Drug Targets Enhancing Endothelial Progenitor Cell Function Through Selective Estrogen Receptor Modulation: A Potential Approach to Cardiovascular Risk Reduction
Cardiovascular & Hematological Agents in Medicinal Chemistry COVID-19: The Significance of Platelets, Mitochondria, Vitamin D, Serotonin and the Gut Microbiota
Current Medicinal Chemistry The Effects of Antihypertensive Therapy on Haemostatic Parameters
Current Pharmaceutical Design Restoring the Dysfunctional Endothelium
Current Pharmaceutical Design Pharmacogenetically Tailored Treatments for Heart Disease
Current Pharmaceutical Design The Hypothalamic-Neurohypophyseal System: Current and Future Treatment of Vasopressin and Oxytocyn Related Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)